Chronic leptin supplementation ameliorates pathology and improves cognitive performance in a transgenic mouse model of Alzheimer's disease

Manuscript Number: 

9-1090R1

Author(s): 
J. Wesson Ashford, Kathryn J. Bryan, Gemma Casadesús, Steven J. Greco, Jane M. Johnston, Sraboni Sarkar, Mark A. Smith, Nikolaos Tezapsidis, Xiongwei Zhu

Disclosures

J. Wesson Ashford

  • Consulting Fees:
    $2,000 paid as consultant in last 2 years by Neurotez.
    Equity:
    Shares owned in Neurotez. Shares owned in Satoris.

Kathryn J. Bryan

  • Nothing to Disclose

Gemma Casadesús

  • Nothing to Disclose

Steven J. Greco

  • Equity:
    Holder of Neurotez common stock
    Sponsors:
    Neurotez sponsored the study

Jane M. Johnston

  • Equity:
    Holder of Neurotez common stock
    Sponsors:
    Neurotez sponsored the study

Sraboni Sarkar

  • Nothing to Disclose

Mark A. Smith

  • Consulting Fees:
    Advana Science; Anavex Life Sciences Corporation; Medivation, Inc.; Neurotez
    Equity:
    Neuropharm, Neurotez, Panacea Pharmaceuticals, Voyager Pharmaceutical Corporation
    Lecture Fees:
    Medivation/Pfizer

Nikolaos Tezapsidis

  • Equity:
    Holder of Neurotez common stock
    Sponsors:
    Neurotez sponsored the study
    Patents/Royalties
    Patents pending

Xiongwei Zhu

  • Nothing to Disclose